Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer-selective photoimmunotherapy spares T cells and NK cells and promotes antitumor immunity in an allogeneic human 3D culture model.

Photochemistry and photobiology·2026

Same author

The adaptive state determines the impact of mutations on evolving populations.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis.

Molecular cancer therapeutics·2025

Same author

Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells.

Cancer immunology research·2025

Same author

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion.

Journal for immunotherapy of cancer·2025

Same author

Dissecting the Spatially Restricted Effects of Microenvironment-Mediated Resistance on Targeted Therapy Responses.

Cancers·2024

Search research articles

Related Experiment Video

Updated: Jan 9, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling.

Nina Obertopp^1,2, Matthew Froid^1,3, Shari Pilon-Thomas²

¹Cancer Biology Ph.D. Program, University of South Florida, Tampa, Florida, USA.

Biorxiv : the Preprint Server for Biology

|December 3, 2025

Summary

Optimizing blinatumomab dosing with treatment-free intervals (TFIs) is crucial for relapsed/refractory B-cell acute lymphoblastic leukemia. Shorter TFIs and Monday-through-Friday schedules show superior tumor control compared to longer intervals.

More Related Videos

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration

Published on: May 24, 2024

An In Vitro Model of the Blood-brain Barrier Using Impedance Spectroscopy: A Focus on T Cell-endothelial Cell Interaction

An In Vitro Model of the Blood-brain Barrier Using Impedance Spectroscopy: A Focus on T Cell-endothelial Cell Interaction

Published on: December 8, 2016

Related Experiment Videos

Last Updated: Jan 9, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration

Published on: May 24, 2024

An In Vitro Model of the Blood-brain Barrier Using Impedance Spectroscopy: A Focus on T Cell-endothelial Cell Interaction

An In Vitro Model of the Blood-brain Barrier Using Impedance Spectroscopy: A Focus on T Cell-endothelial Cell Interaction

Published on: December 8, 2016

Area of Science:

Immunotherapy
Computational Biology
Oncology

Background:

Blinatumomab, a CD3/CD19 bispecific T cell engager (TCE), shows efficacy in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
T cell exhaustion limits blinatumomab response rates.
Treatment-free intervals (TFIs) may enhance blinatumomab therapeutic outcomes.

Purpose of the Study:

To systematically evaluate alternative TFI strategies for blinatumomab dosing.
To optimize TCE dosing strategies through computational modeling.

Main Methods:

Development of an agent-based model (ABM) simulating tumor-T cell interactions.
Calibration of the ABM using in vitro data and incorporation of mechanistic rules for T cell dynamics.
Simulation of various blinatumomab dosing regimens, including different TFIs.

Main Results:

A 7-day TFI improved T cell function initially but lost advantage over a full 42-day cycle.
Shorter TFIs consistently outperformed 7-day and continuous schedules, yielding superior tumor control.
A Monday-through-Friday (MO_FR) regimen demonstrated comparable benefits to shorter TFIs.

Conclusions:

The 7-day TFI schedule may not be optimal for blinatumomab therapy.
Shorter TFIs and schedules like MO_FR may offer greater therapeutic benefit.
Agent-based modeling is valuable for preclinical immunotherapy design and optimizing TCE dosing strategies.